Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cambodia, Myanmar and Iran get EC medical technology aid:

This article was originally published in Clinica

Executive Summary

Medical technology features prominently in a E7.3m ($7.2m) package of humanitarian aid awarded last week to Cambodia, Myanmar and Iran. Under the European Union's ECHO programme, Cambodia will get E4.8m to provide essential supplies, including medical equipment, to help palliate "significant needs [in] access to healthcare" among its 7.5 million inhabitants. Most of the E2m awarded to Myanmar (formerly Burma) will be used to provide medical and diagnostics equipment, primarily to help fight malaria. There is a high prevalence of the disease among the country's more than 35 million population, with the most lethal strain accounting for 80% of cases. Iran will get E0.5m in medical kits and other supplies to help in its recovery from the earthquake of June 2002.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT067778

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel